9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Mithramycin for Lung, Esophagus, and Other Chest Cancers

Mithramycin for Lung, Esophagus, and Other Chest Cancers

Estimated reading time: < 1 min

Condition: Lung Cancer

Estimated Enrollment: 57

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Objective response rate,  Safety,  Pharmacokinetics,

Interventions: Mithramycin,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: August 1, 2025

Completion Date: December 31, 2030

Last  Posted Date: July 31, 2019

Location: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT01624090

Was this article helpful?
Dislike 0